References
1. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in
neonates and children: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines. Chest. 2012;141(2
Suppl):e737S-e801S.
2. Monagle P, Cuello CA, Augustine C, et al. American Society of
Hematology 2018 Guidelines for management of venous thromboembolism:
treatment of pediatric venous thromboembolism. Blood Adv.2018;2(22):3292-3316.
3. Kahn SR, Solymoss S, Lamping DL, Abenhaim L. Long-term outcomes after
deep vein thrombosis: postphlebitic syndrome and quality of life.J Gen Intern Med. 2000;15(6):425-429.
4. van Korlaar IM, Vossen CY, Rosendaal FR, et al. The impact of venous
thrombosis on quality of life. Thrombosis research.2004;114(1):11-18.
5. van Korlaar I, Vossen C, Rosendaal F, Cameron L, Bovill E, Kaptein A.
Quality of life in venous disease. Thrombosis and haemostasis.2003;90(1):27-35.
6. Lubberts B, Paulino Pereira NR, Kabrhel C, Kuter DJ, DiGiovanni CW.
What is the effect of venous thromboembolism and related complications
on patient reported health-related quality of life? A meta-analysis.Thrombosis and haemostasis. 2016;116(3):417-431.
7. Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of
health-related quality of life in patients with deep venous thrombosis.Arch Intern Med. 2005;165(10):1173-1178.
8. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in
venous thromboembolism in children’s hospitals in the United States from
2001 to 2007. Pediatrics. 2009;124(4):1001-1008.
9. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or
Thromboembolic Disease: Implications for Prevention, Antithrombotic
Therapy, and Follow-up. J Am Coll Cardiol. 2020.
10. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe
Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute
Respiratory Failure. Thrombosis and haemostasis. 2020.
11. Connors JM, Levy JH. COVID-19 and its implications for thrombosis
and anticoagulation. Blood. 2020.
12. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical
Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. The New
England journal of medicine. 2017;377(23):2240-2252.
13. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional
catheter-directed thrombolysis versus standard treatment for acute
iliofemoral deep vein thrombosis (the CaVenT study): a randomised
controlled trial. Lancet (London, England). 2012;379(9810):31-38.
14. Notten P, Ten Cate-Hoek AJ, Arnoldussen C, et al.
Ultrasound-accelerated catheter-directed thrombolysis versus
anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a
single-blind, multicentre, randomised trial. The Lancet
Haematology. 2020;7(1):e40-e49.
15. Dandoy CE, Kukreja KU, Gruppo RA, Patel MN, Tarango C. Outcomes in
children with deep vein thrombosis managed with percutaneous
endovascular thrombolysis. Pediatric radiology.2015;45(5):719-726.
16. Gaballah M, Shi J, Kukreja K, et al. Endovascular Thrombolysis in
the Management of Iliofemoral Thrombosis in Children: A
Multi-Institutional Experience. Journal of vascular and
interventional radiology : JVIR. 2016;27(4):524-530.
17. Goldenberg NA, Branchford B, Wang M, Ray C, Jr., Durham JD,
Manco-Johnson MJ. Percutaneous mechanical and pharmacomechanical
thrombolysis for occlusive deep vein thrombosis of the proximal limb in
adolescent subjects: findings from an institution-based prospective
inception cohort study of pediatric venous thromboembolism.Journal of vascular and interventional radiology : JVIR.2011;22(2):121-132.
18. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A
thrombolytic regimen for high-risk deep venous thrombosis may
substantially reduce the risk of postthrombotic syndrome in children.Blood. 2007;110(1):45-53.
19. Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Göttl
U. Definition of clinical efficacy and safety outcomes for clinical
trials in deep venous thrombosis and pulmonary embolism in children.Journal of thrombosis and haemostasis : JTH. 2011;9(9):1856-1858.
20. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome:
evidence-based prevention, diagnosis, and treatment strategies: a
scientific statement from the American Heart Association.Circulation. 2014;130(18):1636-1661.
21. Avila ML, Pullenayegum E, Williams S, Yue N, Krol P, Brandão LR.
Postthrombotic syndrome and other outcomes of lower extremity deep vein
thrombosis in children. Blood. 2016;128(14):1862-1869.
22. Loja MN, Brunson A, Li CS, et al. Racial disparities in outcomes of
endovascular procedures for peripheral arterial disease: an evaluation
of California hospitals, 2005-2009. Ann Vasc Surg.2015;29(5):950-959.
23. Lemaire A, Cook C, Tackett S, Mendes DM, Shortell CK. The impact of
race and insurance type on the outcome of endovascular abdominal aortic
aneurysm (AAA) repair. Journal of vascular surgery.2008;47(6):1172-1180.
24. White RH, Dager WE, Zhou H, Murin S. Racial and gender differences
in the incidence of recurrent venous thromboembolism. Thrombosis
and haemostasis. 2006;96(3):267-273.
25. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with
standard anticoagulants for the treatment of acute venous
thromboembolism in children: a randomised, controlled, phase 3 trial.The Lancet Haematology. 2019.
26. Tarango C, Manco-Johnson MJ. Pediatric Thrombolysis: A Practical
Approach. Front Pediatr. 2017;5:260.
27. Fleming GA, Khan M, Janssen D, Doyle T. Angiojet rheolytic
thrombectomy in infants following cardiac surgery. Catheter
Cardiovasc Interv. 2010;76(2):233-240.
28. Dwarka D, Schwartz SA, Smyth SH, O’Brien MJ. Bradyarrhythmias during
use of the AngioJet system. Journal of vascular and interventional
radiology : JVIR. 2006;17(10):1693-1695.
29. Sarper N, Zengin E, Aylan S, Gelen, Babaoglu K. PB2437 THROMBOLYTIC
THERAPY IN PEDIATRIC PATIENTS; OUTCOME AND COMPLICATIONS OF TISSUE
PLASMINOGEN ACTIVATOR. HemaSphere. 2019;3(S1):1079-1080.
30. Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Recommendations
for tPA thrombolysis in children. On behalf of the Scientific
Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and
Standardization Committee of the International Society of Thrombosis and
Haemostasis. Thrombosis and haemostasis. 2002;88(1):157-158.
31. Ansah DA, Patel KN, Montegna L, Nicholson GT, Ehrlich AC, Petit CJ.
Tissue Plasminogen Activator Use in Children: Bleeding Complications and
Thrombus Resolution. The Journal of pediatrics.2016;171:67-72.e61-62.
32. Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy
in pediatric patients: a comprehensive review of the literature.Thrombosis and haemostasis. 1996;76(2):132-134.
33. Andrew M, Paes B, Milner R, et al. Development of the human
coagulation system in the full-term infant. Blood.1987;70(1):165-172.
34. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by
thrombolytic agents is impaired in newborns due to a low plasminogen
concentration. Thrombosis and haemostasis. 1992;68(3):325-330.